Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 26;620(7974):607–614. doi: 10.1038/s41586-023-06333-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 10 — a, Schema of re-analysis of TCGA breast cancer (BRCA) cohort (Methods). b, Representative copy number plots in der(1;16)(+) cancers analysed using CNACS. c, Distribution of PAM50 molecular subtypes in all cancers (n = 610), IDC (n = 424), and ILC (n = 119), with and without der(1;16), with P-values from two-sided Fisher’s exact test. d, Distribution of morphology, which was compared between der(1;16)(−) and der(1;16)(+) Luminal A cancers using two-sided Fisher’s exact test. e, Proportion of der(1;16)(+) cancer in each PAM50 molecular subtype, and IDC and ILC in all subtypes and Luminal A, respectively, with P-values from two-sided Fisher’s exact test. f,g, Distribution of age (f) and stage (g) in der(1;16)(−) and der(1;16)(+) Luminal A cancer cases, with P-values from two-sided Mann–Whitney U test and Fisher’s exact test, respectively. Box plots show the median, first and third quartiles, with whiskers that extend to the furthest value within a 1.5× interquartile range. h, Kaplan-Meier survival analysis of der(1;16)(−) and der(1;16)(+) Luminal A cancer cases with P-values from two-sided log-rank test. i, Landscape of driver mutations in der(1;16)(−) and der(1;16)(+) Luminal A cancers (n = 220 and 103, respectively). Frequency of each mutation is indicated on the right-hand side. j, Frequency of driver mutations among der(1;16)(−) and der(1;16)(+) cancers in Luminal A IDC (n = 188) and Luminal A ILC (n = 97), respectively. **, q<0.05; *, q<0.1 (from two-sided Fisher’s exact test with Benjamini–Hochberg adjustment). k, Ratio of average expression of genes on 1q in der(1;16)(+) Luminal A tumours (n = 103) to those in 1q-diploid Luminal A tumours (n = 77) was depicted on the top, and the ratio of genes on 16q in der(1;16)(+) Luminal A tumours (n = 51) to those in 16q-diploid Luminal A tumours (n = 83) was depicted on the bottom. Coloured dots indicate known oncogenes, tumour suppressor genes, or other genes on the NOTCH and WNT signalling pathways.

Source Data